Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF02245738PMID 2392503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dysbalance of neuronal second messenger function in the aetiology of affective disorders: A pathophysiological concept hypothesising defects beyond first messenger receptors

  2005cited by this paper
• Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain

  2005cited by this paper
• Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors

  2004cited by this paper
• The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re‐uptake site

  1989cited by this paper
• Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram.

  1989cited by this paper
• Is Phosphodiesterase inhibition a new mechanism of antidepressant action?

  1988cited by this paper
• Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach.

  1988cited by this paper
• Rolipram in major depression: results of a double-blind comparative study with amitriptyline

  1988cited by this paper
• Sensitivity of a cAMP PDE to Rolipram in Different Organs

  1987cited by this paper
• Stereospecific binding of the antidepressant rolipram to brain protein structures.

  1986cited by this paper
• Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.

  1986cited by this paper
• Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions.

  1984cited by this paper
• TVX 2706 — a new phosphodiesterase inhibitor with antiinflammatory action Biochemical characterization

  1984cited by this paper
• Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation.

  1984cited by this paper
• Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.

  1983cited by this paper
• CYCLIC NUCLEOTIDE PHOSPHODIESTERASE IN RAT NEOSTRIATUM: MULTIPLE ISOELECTRIC FORMS WITH SIMILAR KINETIC PROPERTIES

  1976cited by this paper
• The effect of a number of drugs with different pharmacological properties upon reserpine induced hypothermia in mice.

  1971cited by this paper
• Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents.

  1967cited by this paper
• A SIMPLE SCREENING PROCEDURE FOR IMIPRAMINE-LIKE ANTIDEPRESSANT AGENTS.

  1963cited by this paper

• Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.

  2022cites this paper
• Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations

  2021cites this paper
• Advances in the development of phosphodiesterase-4 inhibitors.

  2020cites this paper
• Phosphodiesterase inhibitors: history of pharmacology.

  2011cites this paper
• Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.

  2009cites this paper
• The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens

  2009influential citation
• In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.

  2007cites this paper
• CDP840

  2007cites this paper
• Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats

  2006cites this paper
• Medicinal Chemistry of PDE4 Inhibitors

  2006cites this paper
• Phosphodiesterase-4 as a Pharmacological Target Mediating Antidepressant and Cognitive Effects on Behavior

  2006cites this paper
• PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.

  2005cites this paper
• Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

  2004cites this paper
• Antidepressant-Induced Increase in High-Affinity Rolipram Binding Sites in Rat Brain: Dependence on Noradrenergic and Serotonergic Function

  2003cites this paper
• Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.

  2002cites this paper
• First highly regio- and diastereoselective [3+2] cycloaddition of chiral nonracemic Fischer carbene complexes with azomethine ylides: an enantioselective synthesis of (+)-rolipram.

  2001cites this paper
• Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats.

  2001cites this paper
• Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats

  2001cites this paper
• Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.

  2000cites this paper
• Synthesis and biological evaluation of 2,5-dihydropyrazol.

  2000cites this paper
• Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

  2000cites this paper
• Phosphodiesterase Type 4 Inhibitors

  2000cites this paper
• Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?

  2000cites this paper
• The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.

  2000cites this paper
• Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.

  1999cites this paper
• The therapeutic potential of PDE4 inhibitors.

  1999cites this paper
• Imaging of cAMP‐specific phosphodiesterase‐IV: Comparison of [11C]Rolipram and [11C]Ro 20–1724 in rats

  1999cites this paper
• Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.

  1999cites this paper
• Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors

  1999cites this paper
• Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats.

  1999cites this paper
• Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.

  1998cites this paper
• Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.

  1998cites this paper
• SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

  1998cites this paper
• The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.

  1998cites this paper
• Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.

  1998cites this paper
• 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

  1998cites this paper
• 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.

  1998cites this paper
• Orally active indole N-oxide PDE4 inhibitors.

  1998cites this paper
• Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.

  1997cites this paper
• Stimulation of the hypothalamo‐pituitary‐adrenal axis in the rat by three selective type‐4 phosphodiesterase inhibitors: in vitro and in vivo studies

  1997cites this paper
• Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

  1997cites this paper
• Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin‐2 release from murine splenocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer

  1997cites this paper
• Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons.

  1997cites this paper
• Rolipram, a Selective Phosphodiesterase Type‐IV Inhibitor, Prevents Induction of Heat Shock Protein HSP‐70 and hsp‐70 mRNA in Rat Retrosplenial Cortex by the NMDA Receptor Antagonist DizociIpine

  1997cites this paper
• Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.

  1996cites this paper
• Diminished Noradrenergic Stimulation Reduces the Activity of Rolipram‐Sensitive, High‐Affinity Cyclic AMP Phosphodiesterase in Rat Cerebral Cortex

  1996cites this paper
• Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.

  1996cites this paper
• Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition.

  1996cites this paper
• Phosphodiesterase type IV inhibitors.

  1996cites this paper
• Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.

  1996cites this paper
• Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer

  1996cites this paper
• The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

  1995cites this paper
• Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.

  1995cites this paper
• Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram.

  1995cites this paper
• The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.

  1995cites this paper
• Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.

  1995cites this paper
• Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.

  1995cites this paper
• Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.

  1994cites this paper
• Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

  1993cites this paper
• Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.

  1993cites this paper
• Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.

  1993cites this paper
• Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog.

  1991cites this paper